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Abstract
It has been reported that the immune response mediated by T CD8+ lymphocytes plays a
critical role in the control of Trypanosoma cruzi infection and that the clinical symptoms of
Chagas disease appear to be related to the competence of the CD8+ T immune response
against the parasite. Herewith, in silico prediction and binding assays on TAP-deficient T2
cells were used to identify potential HLA-A*02:01 ligands in the T. cruzi TcCA-2 protein.
The TcCA-2-specific CD8+ T cells were functionality evaluated by Granzyme B and cytokine
production in peripheral blood mononuclear cells (PBMC) from Chagas disease patients
stimulated with the identified HLA-A*02:01 peptides. The specific cells were phenotypically
characterized by flow cytometry using several surface markers and HLA-A*02:01 APC-la-
beled dextramer loaded with the peptides. In the T. cruzi TcCA-2 protein four T CD8+ epi-
topes were identified which are processed and presented during Chagas disease.
Interestingly, a differential cellular phenotypic profile could be correlated with the severity of
the disease. The TcCA-2-specific T CD8+ cells from patients with cardiac symptoms are
mainly effector memory cells (TEM and TEMRA) while, those present in the asymptomatic
phase are predominantly naive cells (TNAIVE). Moreover, in patients with cardiac symptoms
the percentage of cells with senescence features is significantly higher than in patients at
the asymptomatic phase of the disease. We consider that the identification of these new
class I-restricted epitopes are helpful for designing biomarkers of sickness pathology as
well as the development of immunotherapies against T. cruzi infection.
PLOS ONE | DOI:10.1371/journal.pone.0122115 March 27, 2015 1 / 18
a11111
OPEN ACCESS
Citation: Egui A, Thomas MC, Carrilero B, Segovia
M, Alonso C, Marañón C, et al. (2015) Differential
Phenotypic and Functional Profiles of TcCA-2
-Specific Cytotoxic CD8+ T Cells in the Asymptomatic
versus Cardiac Phase in Chagasic Patients. PLoS
ONE 10(3): e0122115. doi:10.1371/journal.
pone.0122115
Academic Editor: Patricia Talamas-Rohana, Centro
de Investigacion y de Estudios Avanzados del
Instituto Politecnico Nacional, MEXICO
Received: December 19, 2014
Accepted: February 22, 2015
Published: March 27, 2015
Copyright: © 2015 Egui et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was supported by grants
SAF2012-35777 and SAF2013-48527-R from
Programa Estatal I+D+i (MINECO); Network of
Tropical Diseases Research RICET, grants RD12/
0018/0021 and RD12/0018/0018 (MSSSI, Spain) and
FEDER. MS and BC were also supported by grant
FIS, 2009SGR385 from ISCIII (MSSSI, Spain). Co-
author Concepción Marañón is employed by
Introduction
Trypanosoma cruzi is the etiological agent of the Chagas disease (ChD), which affects at least 8
million people in Central and South America [1]. In this geographic area more than 25 million
people are at risk of infection. The increasing number of migrants from Latin-American coun-
tries has globally spread the T. cruzi infection to non-endemic areas. Thus, the ChD represents
an important global health problem [2,3]. The disease courses with various clinical forms. The
acute phase appears shortly after infection. In the absence of treatment, the acute phase is fol-
lowed by an asymptomatic phase in which the parasites are present into specific tissues [4]. In
about 30% of patients, the infection leads to a symptomatic chronic phase, characterized by se-
vere cardiac and digestive involvements [5,6].
To date, the efficacy of the current and the rather toxic anti-parasitic chemotherapy is
under concern in patients in the chronic phase of the disease [7,8]. Based on clinical and im-
munological evidence, the World Health Organization and several scientific networks recom-
mend the use of anti-parasite treatments in all chronic-phases of T. cruzi infected individuals
[9]. However, the efficacy of the available current drugs against the chronic phase of the disease
is under study. Likewise, recent clinical trials with new drugs such as azoles are disappointing
[10,11]. In addition, vaccines or immunotherapeutic agents for prevention and treatment of T.
cruzi infection are practically non-existing [12]. Given the magnitude of the disease, accurate
and safe therapeutic agents able to control the infection are extremely urgent.
The effector functions mediated by T lymphocytes are essential for the control of the para-
site proliferation. Thus, the initial activation of CD4+ T lymphocytes, the subsequent activation
and proliferation of T CD8+ lymphocytes and the activation of B lymphocytes play a crucial
role in the control of the parasite replication [13]. In experimental models of infection it has
been shown that the induction of cellular immunity and, particularly, the response mediated
by T CD8+ lymphocytes is crucial for the control of T. cruzi proliferation [14,15]. Although
several parasite class I-restricted antigenic epitopes have been characterized in murine experi-
mental models [16], the CD8+ response in Chagas patients is limited to a few epitopes [17–21].
In fact, the information about the function and phenotype of CD8+ T cells recognizing these
few epitopes is very incomplete [22]. It is also known that during T. cruzi infection the parasite
restricts the repertoire of CD8+ T cells that generate strong immunodominance [23]. It has
been suggested, in addition, that the immunological restriction is a mechanism probably used
by the parasite to reduce the magnitude of the immune response of the host favoring, thus, par-
asitism [23]. It seems, furthermore, that during natural infection the immune response is not
strong enough to attain sterility since the parasites persist hidden into particular patient´s tis-
sues [24,25].
The parasite clearance observed in treated mice results in the emergence of a stable, para-
site-specific CD8+ T cell population with the characteristic of central memory cells, based upon
expression of CD62L, CD122 and CD127 [26]. Many criteria have been used to characterize
the antigen-experienced memory CD8+ T cells including the expression of the activation mark-
er CD45RA, the homing receptor CCR7, the co-stimulatory molecule CD27 and the IL7 cyto-
kine receptor (CD127) [27–29]. The CD127+ antigen-specific CD8+ T cells present in T. cruzi
infected mice produce IFN-γ after peptide re-stimulation and are persistent when transferred
to an antigen-free environment [30]. Since a significant higher clinical score has been observed
in patients with low CD8+ T lymphocytes able to produce IFN-γ in response to T. cruzi parasite
it seems that the clinical symptoms of Chagas disease are directly related to the efficiency of the
immune response against the parasite. In individuals having a severe chronic T. cruzi infection
the low CD8+ T cells count has been mainly associated to an increased differentiation of mem-
ory CD8+ T cells (CD27-CD28-CD45RA-) as well as to a clonal deployment [31].
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In the present paper we describe the identification of four T CD8+ epitopes restricted to the
HLA-A02:01 molecule in the T. cruzi TcCA-2 protein. The TcCA-2 protein, as well as the ho-
mologous TCR39 and B13 antigens, contains a track of N-terminal 12 aa imperfect repetition
motif [32,33], which seems to possess a significant degree of antigenicity and to be a target of
B-cell responses. Actually, the repetition motifs are being used as diagnostic tools [32,34,35], as
well as to assess the severity of the disease [36]. It has also been described that the repetitive do-
mains existing in the B13 antigen is recognized by T cells in the context of several HLA class II
molecules [37]. The four newly identified T CD8+ epitopes are successfully processed and pre-
sented during ChD. The phenotype and functional activity of the identified peptide-specific
CD8+ T cells from chagasic patients, at different phases of the disease, are also analyzed. Re-
markably, a differential phenotypic profile has been observed relative to the severity of the dis-
ease. Thus, the TcCA-2-specific CD8+ T cells from patients with cardiac symptoms are mainly
effector memory cells (TEM and TEMRA) while, those present in patients at the asymptomatic
phase are predominantly naive cells (TNAIVE). Moreover, in patients with cardiac symptoms
the percentage of cells with senescence features (CD44+/CD57+) is higher than that detected in
patients at the asymptomatic phase of the disease.
Materials and Methods
Prediction of HLA-A*02:01 epitopes and synthetic peptides
The prediction of potential HLA-A02:01 ligands in the T. cruzi TcCA-2 protein was per-
formed by analyzing the deduced amino acid sequence of the TcCA-2 gene (GenBank, CAI
strain, accession number M92049.1 and CL Brenner strain, accession number XM813834) fol-
lowing the criteria described by Rammense et al [38]. For the selected epitopes, two in silico
HLA-A02:01 binding prediction algorithms where used, SYFPEITHI to analyze the affinity
(www.syfpeithi.de) and BIMAS to calculate the stability (half-life) of the complex (www-bimas.
cit.nih.gov). These epitopes presented the lowest scores using the Immune Epitope Database
and Analysis Resource (IEDB), where a low score is associated to a high binding affinity
(http://tools.immuneepitope.org/main/html/references.html).
Peptides bearing the described HLA-A02:01 binding motifs were synthesized by simulta-
neous multiple-peptide solid-phase methods. The peptides were assembled using the
standard t-Boc solid-phase-peptide synthesis (SPPS) strategy on a P-metylbenzhydrilamide
(MBHA) resin. Purity was checked by high performance liquid chromatography (HPLC),
and the correct composition of the peptide was verified by mass spectrometry [39]. Peptides
were dissolved to 1 mM final concentration in water containing 10% DMSO and stored at
-20°C.
Cell lines
TAP-deficient T2 cells [40] were used for the HLA-A02:01 binding assays and the K562-A2
cells [41] for the HLA-A02:01 restriction assay. The cells were cultured in complete RPMI me-
dium supplemented with 10% of inactivated Fetal Calf Serum (iFCS), 2 mM glutamine, and
100 U/ml penicillin. K562-A2 cells, expressing the HLA-A02:01 molecule were cultured in the
presence of 0.5 μg/ml of G-418, as previously described [41]. The T2 and K562-A2 cells were
kindly provided by Dr. Pedro Romero (University of Lausanne) and by Dr Peter Ponsaerts
(University of Antwerp, with the permission of Dr. Cedrik Britten from Johanes Gutenberg-
University Mainz), respectively.
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Study populations
For the screening of the recognition of TcCA-2 epitopes by Chagas disease patients, 10
HLA-A02:01 adult patients in the asymptomatic phase of the disease (IND) were enrolled.
For cytotoxicity, functional activity determinations and phenotypic characterization another
group of 19 HLA-A02:01 adults Chagas disease patients and 9 healthy donors were analyzed.
These patients were at the chronic stage of the disease and were considered to be at the asymp-
tomatic phase (IND, n = 8) if there was no evidence of having cardiac or gastrointestinal disor-
ders. Chronic Chagas cardiomyopathy patients (CCC, n = 11) were stratified into G1 to G3
stages following Kuschnir classification according to clinical criteria and radiological, electro-
cardiographic and echocardiography analyses. The number of patients was the one recom-
mended by the Hospital Ethical Committee. The committee suggested that the amount of
patients to be included in the study should be the minimal number that provides a statistically
significant result. The patients were enrolled in both studies (functional and phenotypic char-
acterization, IND n = 6 and CCC n = 7) when the available number of purified PBMC (limited
by the cellular number isolated from each subject) was enough for both analyses. Another four
CCC patients had to be enrolled to perform the phenotypic analysis in order to reach
statistical significance.
These patients were Spain-residents coming from endemic areas, diagnosed for Chagas dis-
ease following WHO criteria using two conventional serological tests (Chagas ELISA, Ortho
Clinical Diagnosis and Inmunofluor Chagas, Biocientífica, Argentina) at Hospital Virgen de la
Arrixaca (Murcia-Spain), and that had never received treatment for the disease. HLA-A2-0201
patients selection was made at random among those that were positive after serological tests.
These patients were clinically characterized in detail. Thirteen mL of blood samples from each
patient were collected in EDTA. Peripheral blood mononuclear cells (PBMC) were purified as
previously described in [21], stored in iFCS with 10% DMSO and cryopreserved in liquid nitro-
gen until use. HLA-A genotyping was carried out using the RELITM SSO HLA-A Typing kit
(Invitrogen).
Ethical considerations
The protocols were approved by the Ethical Committees at Hospital Clínic, Hospital Virgen de
la Arrixaca and Consejo Superior de Investigaciones Científicas (Spain). A signed informed
consent was obtained from all individuals prior to their inclusion in the study.
HLA-A*02:01 binding assay
HLA-A02:01 surface stabilization test was carried out as described in [42]. Briefly, TAP-
deficient T2 cells were loaded with different concentrations of each peptide, in duplicate in
serum-free RPMI medium, and incubated overnight at room temperature. Afterwards, the cells
were stained with a PE-labeled HLA-A2-specific antibody (BB7.2 clone, BD biosciences) and
analyzed by flow cytometry. The high-affinity HLA-A02:01-binding peptide HB-ENV334–342
(WLSLLVPFV) was included as internal standard [43]. Affinity data were calculated as the per-
centage of maximum complex stabilization, as described in [44]. The following equation was
used: % of maximal stabilization = 100 x [(mean fluorescence with peptide)–(background
mean fluorescence)]/[(mean fluorescence with 25 μMHBENV335-343 peptide)–(background
mean fluorescence)]. Background value was obtained with cells incubated in the same condi-
tions without peptide [42].
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Granzyme B secretion in peripheral blood mononuclear cells from
Chagas disease patients
The frequency of Granzyme B (GzB) producing cells was evaluated by ELISPOT assays using
cryopreserved PBMC from Chagas disease patients and healthy donors as control. This proto-
col was carried out as described in [20]. Briefly, 96-well PVDF membrane-bottom plates (Milli-
pore) were pre-wetted with 35% ethanol and washed five times with PBS. Subsequently, plates
were coated with 100 μL of anti-GzB (5 μg/mL) monoclonal antibody (Mabtech) and incubated
overnight at 4°C. Plates were washed with PBS and incubated with 200 μL/well of blocking so-
lution (RPMI-1640-10% FCS) at room temperature for 30 minutes. Afterwards, 5 × 104
PBMC/well were added and incubated with 1 μM of each peptide for 30 h at 37°C with 5%
CO2, in triplicates. As a positive control, the PBMC were stimulated with 50 ng/ml phorbol
12-myristate 13-acetate (PMA, Sigma) and 500 ng/ml ionomycin (Sigma), or 10 μg/mL of phy-
tohaemaglutinin (PHA, Sigma). Supernatants were harvested and aliquoted at -80°C for subse-
quent cytokine secretion profile determination. After five washes, 100 μL/well of a 1 μg/mL
solution of biotinylated GzB-specific antibody (Mabtech) was added in 0.5% iFCS in PBS, and
the plates were incubated for 2 h at room temperature. Wells were extensively washed with
PBS and incubated with 100 μL/well streptavidin-alkaline phosphatase (Sigma) at dilution of
1:6000 for 1 h at room temperature. After washing (5x) with PBS, 50 μL/well of substrate solu-
tion (NBT-BCIP substrate, Sigma) were added. The wells were incubated for 20–30 min at
room temperature in the dark. The reaction was stopped by rinsing the plates with cold tap
water. The spots were visualized in an AXIO PLAN 2 Imagine microscope and quantified
using KS ELISPOT software. The results are expressed as the number of peptide-induced spots
forming cell (SFC) x106 PBMC after subtracting the spot number of peptide un-stimulated
PBMCs (basal response). The results were considered positive when a minimum of 20 SFCx106
PBMCs and of at least over twofold basal spot numbers were detected.
Cytokine-secretion tests
Cytokine secretion (IL-4, IL-10, IL-6, IFN-γ, TNF-α) was determined in the supernatants of
PBMC from Chagas disease patients and healthy donors, after in vitro stimulation with 1 μM
of each peptide for 30 h at 37°C in RPMI supplemented with 10% iFBS as explained before.
The secretion profile was determined by using a bead-based multiplex immunoassay system
(Bio-Plex, Bio-Rad), following the manufacturer's instructions. The response was considered
positive if an increase in the secretion of cytokines was at least three folds higher than the secre-
tion by un-stimulated cells (basal secretion level) and at least, 4 pg/mL for IL-4, 2 pg/mL for
IL-10, 15 pg/mL for IL-6 and 5 pg/mL for IFN-γ and TNF-α. The positive control consisted of
50 ng/mL Phorbol 12 myristate 13-acetate (PMA) and 500 ng/mL ionomycin (Sigma). Cyto-
kine levels were quantified in each sample by using the Bio-Plex Manager software 4.1 (Bio-
Rad).
In the HLA-A02:01 restriction assay, peptide-pulsed K562-A2 cells were used as antigen-
presenting cells (APC). Plates were seeded with 20,000 peptide-pulsed K562-A2 [41] or K562
cells as a negative control. After washing of non-bound peptide, APC were incubated with
60,000 effector cells per well and the IFN-γ secretion test was performed as mentioned above.
CD8+ T cell peptide-specific phenotypic characterization
TcCA-2-specific CD8+ T cells were characterized using a HLA-A02:01 APC-labeled dextra-
mers loaded with the TcCA-2442-451 and TcCA-2607-615 peptides, respectively (Immudex).
1X106 PBMCs from 17 HLA-A02:01+ Chagas disease patients and 6 healthy donors were
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incubated with 10μL of each dextramer in 40μL of 5% FCS in PBS for10 min at RT in the dark.
Afterwards, these cells were incubated 20 min at 4°C with different cocktails of antibodies (BD
Pharmigen): CD8-V500, CD8 PerCP-Cy5.5, CD45RA-APC-H7, CCR7-V450, CD27-FITC,
CD127-PerCp-Cy5, CD57-FITC and CD44RA-APC. The labeled cells were washed twice with
PBS-5% FCS and resuspended in 400 μL of PBS 1X. Data were acquired in a FacsAria III Cell
Sorter and analyzed using Flowjo 7.6.5 software (Bio-Rad). At least 100.000 PBMC cells were
acquired according to FCS/SSC parameters. The gating strategy is shown in Fig. 1.
Statistical analysis
The statistical analysis was performed using Prism V5.0 (GraphPad Software, La Jolla, CA,
USA). Nonparametric test were used to test for statistical significance. Comparison between
asymptomatic and cardiac Chagas disease patients within the same cell subpopulation was
evaluated by the Mann-Whitney U test (pairwise comparisons). In addition, Kruskal—Wallis
test with Dunn correction was used to identify groups of cellular subpopulations or more than
two groups of subjects (ANOVA for comparisons among> 2 groups). Statistical significance
was assigned at a value of p 0.05.
Results
Selection of HLA-A*02:01-binding peptides within T. cruzi TcCA-2
protein
In order to identify peptides containing potential HLA-A02:01-binding sites, the deduced
amino acid sequence of T. cruzi TcCA-2 was screened following the criteria described by Ram-
mense et al [38] and using two computer algorithms. The SYFPEITHI and (IEDB) algorithms
were employed to analyze binding affinity of the peptides to MHCI HLA-A02:01 and the
BIMAS to analyze the stability of the preformed complex. Eight peptides presented mid-to-
high affinity score for HLA-A02:01 (Table 1) and were consequently synthesized. All these
peptides presented a low percentile rank score using the Immune Epitope Database and Analy-
sis Resource (IEDB), which is associated to a high binding affinity (Table 1).
The percentage of maximal binding stabilization of these eight TcCA-2 peptides was evalu-
ated using TAP-deficient T2 cells and different concentrations of each peptide. The experimen-
tal results were referred with the fluorescence index values obtained with the HB-ENV335–343
peptide as it has been previously shown that this peptide has a high binding affinity to
HLA-A02:01 MHC I [43]. The maximal binding affinity is shown for each peptide in Table 1.
Detection of CD8+ T lymphocytes specific for HLA-A*02:01+
In order to analyze whether the Chagas disease patients CD8+ T cells recognize the TcCA-
2-derived peptides in the context of the HLA-A02:01+ molecule, peptide-pulsed K562-A2
cells were used as APC in a multiplex immunoassay for detection of IFNγ secretion (Table 2).
PBMC from HLA-A02:01+ asymptomatic Chagas disease patients (IND) recognized four
TcCA-2 epitopes (TcCA-2657-666, TcCA-2442-451, TcCA-2607-615 and TcCA-2273-281) while
being presented on K562-A2 but not on K562 cells, which do not express Class I molecules.
Two out of 9 patients responded to the TcCA-2657-666 peptide, 2 out of 10 to the TcCA-2442-451
peptide, 3 out of 9 to the TcCA-2607-615 peptide and 1 out of 10 to TcCA-2273-281.
The cytotoxic activity of the CD8+ T cells specific for these four TcCA-2-derived epitopes
was evaluated by secretion of GzB through ELISPOT assays. Thus, PBMC from 15
HLA-A02:01 chagasic patients (8 IND and 7 CCC) and 9 healthy donors were incubated with
the peptides under study. A positive GzB response was detected in 3 patients (2 IND and 1
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Fig 1. Phenotypic characterization of TcCA-2-specific CD8+ T cells. The dot plots show the lymphocyte
gating based on forward-scatter (FSC) and side-scatter (SSC) properties (A), CD8+ T cell population (B1-C1)
and the percentage of TcCA-2-specific CD8+ T cells (B2-C2) from a healthy control subject (B) and from
chagasic disease patient (C) respectively. The phenotypic analyses of TcCA-2-specific CD8+ T cells, defined
by CD45RA, CCR7, CD27, CD127, CD44 and CD57 expression (D-I) allowed to identify naive
(CD45RA+CD27+CCR7+) and terminal effector memory (TEMRA, CD45RA
+CD27-CCR7-) TcCA-2-specific
CD8 T cells (E), central memory (TCM, CD45RA
-CD27+CCR7+) and effector memory (TEM,
CD45RA-CD27-CCR7-) TcCA-2-specific CD8+ T cells (F), early-stage differentiation (TED, CD45RA
-CD127+)
and advanced-stage differentiation (TTD, CD8
+CD45RA+CD127-) TcCA-2-specific CD8+ T cells (G),
senescent memory (CD44+CD57+) and non-senescent memory (CD44+CD57-) TcCA-2-specific CD8 T cells
(H) and CD27 expression in TcCA-2-specific CD8+T cells (I). Gates were established based on the control
isotypes corresponding to each antibody. Non-stained cells and mononuclear cells incubated with antibodies
but not with dextramers were used as reference to define the cut-off for each specific dextramer labeling.
doi:10.1371/journal.pone.0122115.g001
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CCC) out of 10 in response to incubation with the TcCA-2657-666 peptide, 5 patients (3 IND
and 2 CCC) out of 14 in response to the TcCA-2442-451 peptide, 3 patients (3 CCC) out of 14 in
response to the TcCA-2607-615 peptide and 2 patients (2 IND) out of 11 in response to the
TcCA-2273-281 peptide (Table 3). Cytotoxic activities were not detected in any healthy donor.
Functional analysis of the epitope-specific CD8+ T cells was carried out by the determina-
tion of the secretion profile of IFN-γ, TNF-α, IL-4, IL10 and IL-6 cytokines. The results, pre-
sented in Table 3, show that CD8+ T cells from 2 out of 14 patients recognized peptides TcCA-
2442-451 by secreting IFN-γ, TNF-α and IL-6 and 2 out of 14 by secreting TNF-α and IL-6. The
Table 1. Sequences of the TcCA-2-derived HLA-A*02:01 binding peptides.
Code Position (aa) Sequence a SYFPEITHI BIMAS IEDB % maximal
peptide score score score stabilization
12828 TcCA-2 273–281 AAAGDKLSL * 23 0.29 18.00 12.41
12822 TcCA-2442-451 TVFDASRSTV 18 18.46 4.55 24.44
12823 TcCA-2452-461 FANAPGVAQV 22 10.22 6.50 46.23
12824 TcCA-2489-498 SILQNVHATL 26 10.86 3.80 36.02
12825 TcCA-2531-540 AIGGGKLPAL 28 6.75 6.90 20.89
12826 TcCA-2550-559 SAFGNHASTV 21 3.57 7.15 19.07
12827 TcCA-2607-615 ALRNLRVFL 24 8.92 6.80 29.54
12819 TcCA-2657-666 ALQVTNHRYL 22 23.49 7.00 21.49
The table shows the theoretical binding score to HLA-A*02:01 calculated by the computer algorithms SYFPEITHI and Immune Epitope Database and
Analysis Resource (IEDB). The half time of complex disassociation (expressed in minutes) was calculated by the BIMAS algorithm. The maximal binding
stabilization was calculated referred to HB-ENV335-343 peptide as a control.
a Deduced amino acid from the sequence as found in GenBank, accession number: M92049.1. The sequence starts from the nucleotide 566 and ends on
nucleotide 2461.
* The sequence encoding the peptide TcCA-2273-281 is contained in position 817–843 of the nucleotide sequence of the CL Brenner strain (accession
number XM-813834).
doi:10.1371/journal.pone.0122115.t001
Table 2. Recognition of TcCA-2 epitopes by HLA-A*02:01 Chagas disease patients.
Peptide Chagas disease patienta INF-γ secretion range (pg/mL)b
TcCA-2273-281 1/10 8.6
TcCA-2442-451 2/10 5.8–6.9
TcCA-2452-461 0/10 -
TcCA-2489-498 0/8 -
TcCA-2531-540 0/9 -
TcCA-2550-559 0/9 -
TcCA-2607-615 3/9 6.4–15.1
TcCA-2657-666 2/9 6.1–6.7
K562-A2 cells were pulsed with 1 mM of each peptide for 1 h, and co-cultured with PBMCs from
asymptomatic HLA-A*02:01 Chagas disease patients. Following 30 h of growth, IFN-γ secretion was
measured in the supernatants. IFN-γ secretion level in K652 cells, not expressing the class I molecule, was
subtracted from the values obtained in the assays with the K562-A2 cells loaded with peptides.
Responses were considered positive when the supernatant IFN-γ concentration of the peptide-stimulated
cells was at least two folds the concentration of the un-stimulated cells (non-peptide).
a Patients with positive response, in relation with the total number of patients per assay.
b Range of IFN-γ secretion by patients with a positive response to TcCA-2 peptides.
doi:10.1371/journal.pone.0122115.t002
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Table 3. Cytokine-secretion and Granzyme B response to TcCA-2 epitopes by PBMCs from HLA-A*02:01 Chagas disease patients and healthy
donors.
Clinical Code IL6 IFNγ TNFα GzBc Clinical Code IL6 IFNγ TNFα GzBc
forma patient (pg/mL)b (SFC/106) forma patient (pg/mL)b (SFC/106)
TcCA-2273-281 TcCA-2607-615
HD 340 9 0 4 0 HD 340 6 0 0 0
HD 008 9 -1 0 -47 HD 008 22 3 0 -70
HD 664 0 -3 0 0 HD 664 0 -3 0 0
HD 001 1 6 -8 1 HD 001 -6 1 -14 0
HD 006 1 6 2 -7 HD 006 69 13 5 7
HD 005 -183 -19 -11 -47 HD 005 -77 -21 -2 -47
HD 004 -9 0 0 0 HD 004 -5 0 0 -7
HD 011 -11 0 -8 -20 HD 011 -12 0 -8 -7
IND 571 0 0 0 67 IND 535 -5 0 -1 -7
IND 535 -5 0 -1 -27 IND 265 1127 81 83 -100
IND 388 36 2 7 33 IND 283 55 15 26 -20
IND 365 43 1 -6 7 IND 388 32 1 -11 13
IND 510 1 0 -1 -20 IND 365 23 5 23 7
IND 917 18 7 11 13 IND 510 -1 0 2 13
CCC I 861 -4 2 -2 8 IND 917 -2 1 -3 -20
CCC I 884 0 0 0 7 CCC I 861 -7 0 -3 -8
CCC I 456 0 0 0 13 CCC I 884 0 0 0 0
CCC I 770 22 0 4 -7 CCC I 456 18 3 12 13
CCC III 509 -4 0 -5 0 CCC I 770 49 0 16 0
TcCA-2442-451 CCC II 142 -4 0 -15 53
HD 340 11 2 3 1 CCC III 797 9 -5 3 27
HD 008 31 1 15 -73 CCC III 509 -5 0 -4 25
HD 664 0 -3 0 1 TcCA-2657-666
HD 001 18 4 -6 0 HD 340 22 1 8 1
HD 006 -2 2 2 -7 HD 008 3 -3 -21 -47
HD 005 16 5 -1 -40 HD 664 0 -3 0 0
HD 004 -15 0 -1 0 HD 017 0 0 0 0
HD 011 54 8 10 -20 HD 001 1 -2 -6 0
IND 535 -6 0 -1 -13 HD 006 -5 3 1 0
IND 265 1641 204 160 -13 HD 005 -58 0 -4 -40
IND 283 80 12 35 47 HD 004 -12 4 -1 -7
IND 388 21 1 -10 0 HD 011 -4 0 0 -7
IND 365 7 0 15 27 IND 571 0 1 0 83
IND 510 1 0 1 0 IND 535 -5 0 -2 67
IND 917 -13 -1 -4 40 IND 388 2 2 -5 7
CCC I 861 -4 0 -3 0 IND 365 10 2 14 0
CCC I 884 0 0 0 7 IND 510 -3 0 1 -7
CCC I 456 46 4 6 -7 IND 917 -17 -1 -17 -10
CCC I 770 3 -2 -11 13 CCC I 861 -4 0 -2 50
CCC II 142 -3 2 -20 80 CCC I 884 0 0 0 0
CCC III 797 31 3 7 7 CCC I 770 1 0 -6 -7
(Continued)
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TcCA-2607-615 peptide was recognized by 2 out of the 14 patients cells, by secreting IFN-γ,
TNF-α and IL-6, 1 out 14 by secreting TNF-α and IL-6 and 1 out 14 by secreting IL6. CD8+ T
cells from 2 out of 11 patients responded to stimulation with peptide TcCA-2273-281 by secret-
ing IL-6. Any production of cytokines was detected after stimulation with the TcCA-2657-666
peptide. There was no secretion of IL-4 and IL-10 in PBMC after stimulation with any one of
the four TcCA-2 peptides (data not shown). IFN-γ, TNF-α and IL6 cytokines secretion levels
were higher in patients at the asymptomatic phase of the disease than in Chagas patients with
associated cardiomyopathy.
Phenotypic characterization of T CD8+ lymphocytes specific for TcCA-2
derived peptides
After having shown the lymphocyte activation capacity of TcCA-2-derived epitopes (TcCA-
2657-666, TcCA-2442-451, TcCA-2607-615, and TcCA-2273-281) we decided to phenotypically char-
acterize, the specific CD8+ T lymphocytes that recognized the two peptides that exhibited the
greatest recognition by specific CD8+ T cells (TcCA-2442-451 and TcCA-2607-615) (scheme in
Material and Methods Section, Fig. 1). With that aim, mononuclear cells from Chagas patients
in different phase of the disease (IND, n = 6 and CCC, n = 11) as well as from healthy donors
(HD, n = 6) were incubated with HLA-A02:01 APC-labeled dextramers loaded with the
TcCA-2442-451 and-TcCA-2607-615 peptides. As shown in Fig. 2A, the percentage of total CD8
+
T lymphocyte in the PBMC gate was significantly higher in asymptomatic Chagas disease pa-
tients (IND) than in healthy donors (p0.05). In addition, we observed that IND and CCC
Chagas disease patients had a higher percentage of TcCA-2442-451 and TcCA-2607-615 specific
CD8+ T cells than healthy individuals (p0.05 and p0.01) (Fig. 2B).
Labeling, using antibodies against CD45RA, CD27 and CCR7 molecules, allowed us to phe-
notypically characterize TcCA-2442-451 and TcCA-2607-615-specific CD8
+ T cells from patients
at different phases of the disease (IND and CCC). Thus, as shown in Fig. 3A1 we observed that
the TcCA-2442-451-specific CD8
+ T cells from IND patients have a higher percentage of cells ex-
pressing the TNAIVE phenotype (CD45RA
+CD27+CCR7+) than the cells from CCC patients
(p0.01). However, the percentage of terminal effector memory CD8+ T cells (TEMRA cells,
CD45RA+CD27-CCR7-) was significantly lower in IND patients than in CCC (p0.05)
(Fig. 3A1). Moreover, the TcCA-2442-451-specific CD8
+ T cells from CCC patients have a higher
percentage of TEMRA cells than that having a phenotype TNAIVE (p0.05). Regarding the
TcCA-2607-615-specific CD8
+ T cells, the percentage of cells expressing CD45RA+CD27+CCR7+
(TNAIVE) was also significantly higher in IND versus CCC patients (p0.01) (Fig. 3B1). The
percentage of TEM is higher in CCC patients than that in IND patients (p0.05). Moreover, the
percentage of TEM versus of TCM cells is also higher in CCC patients than that in IND patients
Table 3. (Continued)
Clinical Code IL6 IFNγ TNFα GzBc Clinical Code IL6 IFNγ TNFα GzBc
forma patient (pg/mL)b (SFC/106) forma patient (pg/mL)b (SFC/106)
CCC III 509 -4 0 -5 50 CCC III 509 -4 0 -5 0
a HLA-A*02:01 Chagas disease patients in asymptomatic phase (IND) and cardiac forms (CCC). HD: HLA-A*02:01 healthy donors. The cytokine
secretion and the number of GzB-secreting cells were calculated by subtracting background levels or the number of spots in control wells (non-peptide)
from the levels measured or the number of spots obtained in the stimulated cultures. Responses were considered positive (in bold) when:
b The cytokine concentration is at least three folds the non-peptide control value and 15 pg/mL for IL-6 and  5 pg/mL for IFN-γ and TNF-α.
c The number of SFC per million was 20 and at least twice the value found in the background control wells.
doi:10.1371/journal.pone.0122115.t003
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(p0.05). In fact, the TcCA-2607-615-specific CD8+ T cells from CCC patients had mainly an ef-
fector phenotype showing a predominant profile of TEM cells versus of TCM cells (p0.05)
(Fig. 3B1). By combining the CD45RA and CD127 surface markers it was observed (Fig. 3A2
and 3B2) that both IND and CCC patients have a higher percentage of TcCA-2442-451 and
TcCA-2607-615—specific CD8
+ T cells at an advanced-stage differentiation (TTD,
CD45RA+CD127-) phenotype than at an early-stage differentiation (TED, CD45RA
-CD127+)
phenotype (p0.01).
Since the CD57 expression is associated with replicative senescence we evaluated the CD57
expression in CD44+ cells (marker of antigen-experience T cells) of both TcCA-2442-451 and
TcCA-2607-615-specific T CD8
+ cells. The results shown in Fig. 4A and 4B indicate that in IND
patients the predominant phenotype is of non-senescent memory cells (CD44+CD57-,
p0.001) and that the percentage of circulating senescent memory cells (CD44+CD57+) specif-
ic for both epitopes is significantly higher in CCC patients than that in IND patients (p0.01).
Discussion
CD8+ T cells are essential for controlling T. cruzi infection [45]. Nevertheless, parasite-derived
antigens capable of inducing CD8+ T cells activation have been characterized mainly in mouse
models [46–48]. By performing an in silico assessment with two independent bioinformatic
Fig 2. TcCA-2442-451 and TcCA-2607-615 CD8
+ specific T cells. (A), percentage of CD8+ T cells in the PBMC region (see Fig. 1C1). (B), peptide-specific cells
of total CD8+ T cells. Cell subpopulations were determined by flow cytometry in 6 healthy donors (HD), 6 patients in the asymptomatic phase (IND) and 11
patients in the cardiac phase (CCC). Median values are represented by horizontal lines. Error bars represent standard deviation intervals. Statistical
analyses were carried out using Kruskal—Wallis test with Dunn correction (*). Statistically significant differences are indicated (*) p0.05, (**) p0.01, (***)
p 0.001.
doi:10.1371/journal.pone.0122115.g002
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algorithms we have identified eight epitopes that theoretically bind to HLA-A02:01 class I
MHCmolecules in the T. cruzi protein TcCA-2. The identification of HLA-A02:01-binding
epitopes was carried out using peptide—pulsed K562-A2 cells as APCs in an IFN-γ secretion
test. The K562-A2 cell line is an inexhaustible source of APCs [41] and efficiently presents
HLA-A02:01 binding peptides to specific CD8+ T cells showing a low level of background re-
activity [49]. The data obtained showed that 4 out of the 8 theoretically HLA-A02:01-binding
epitopes were recognized, processed and presented in the context of a natural T. cruzi infection.
The use of a cellular line as APC instead of the “natural” presenting cells that are present in the
PBMCmay influence the percentage of patients that recognized the different peptides. Taking
into account the secretion level of GzB and IL-6, IFN-γ and TNFα cytokines a two fold increase
Fig 3. Immunophenotyping of memory and differentiation status of the specific CD8+ T cells in patients with Chagas disease. (A) TcCA-2442-451
peptide. (B) TcCA-2607-615 peptide. PBMCs from 6 asymptomatic form patients (IND) and 11 patients with the cardiac form (CCC) were stained for CD45RA,
CD27 and CCR7 and analyzed by flow cytometry. According to the combination of antibodies used the CD8 peptide-specific cells were divided in: TNAIVE
(CD8+CD45RA+CD27+CCR7+), TEMRA (CD8
+CD45RA+CD27-CCR7-), TCM (CD8
+CD45RA-CD27+CCR7+), TEM (CD8
+CD45RA-CD27-CCR7-), TED
(CD8+CD45RA-CD127+), TTD (CD8
+CD45RA+CD127-). Median values are represented by horizontal lines. Error bars represent standard deviation intervals.
Statistical analyses were carried out using Mann-Whitney U test (#) and Kruskal—Wallis test with Dunn correction (*). Statistically significant differences are
indicated (#) or (*) p0.05, (# #) or (**) p0.01, (# # #) or (***) p 0.001.
doi:10.1371/journal.pone.0122115.g003
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of the number of responsive patients was observed when the own patient´ APC were employed.
Interestingly, CD8+ T cells specific for these four epitopes are functionally active in both the
asymptomatic (IND) and the symptomatic (CCC) Chagas disease chronic patients showing a
differential phenotype depending on the severity of the disease. The identification of new class
I-restricted epitopes are helpful for designing biomarkers of sickness pathology as well as the
development of immunotherapies against T. cruzi infection. The fact that only a fraction of pa-
tients responded to particular peptides may be a consequence of the existence of high variabili-
ty regarding the antigen processing and presentation by the Chagas disease patients.
Consequently, the use of several epitopes belonging to others T. cruzi antigens will be required
to perform an accurate disease follow-up. In fact, an increase in the number of responsive pa-
tients and in particular an increase in the multifunctional response capacity (both cytokines se-
cretion and cytotoxic activity) of the epitope-specific CD8+ T cells was detected (data not
shown), when the response against CD8+ T epitopes belonging to other T. cruzi antigens
[20,21] was considered.
The HLA-A02:01-binding in vitro assays using the TAP-deficient T2 cells shows that the
correlation between the theoretical and the in vitro binding data is low. Similarly, low-medium
correlation coefficients have been described between experimental and theoretical
HLA-A02:01-binding data for other T. cruzi antigens [21,50]. The identification of class I epi-
topes has been limited to the HLA-A02:01 molecule due to the fact that it is the most prevalent
human Class I allele [51].
The TcCA-2–specific CD8+ T cells from chronic patients at the asymptomatic and cardiac
phases of the disease have cytotoxic activity. Remarkably, CD8+ T cells specific for the TcCA-
2442-451 and TcCA-2607-615 epitopes also secreted the pro-inflammatory cytokines IFN-γ and
TNFα. The secretion of these cytokines has been correlated to an improved protective CD8+-
mediated immunity against T. cruzi infection [14,52]. In addition, the TcCA-2442-451, TcCA-
2607-615 and TcCA-2273-281–specific CD8
+ T cells from chronic patients secreted IL6 cytokine.
The IL-6 is a pleiotropic cytokine related to inhibition of expansion and functionality of Treg
Fig 4. Expression of the senescencemarker CD57 in antigen-experienced specific CD8+ T cells. (A) TcCA-2442-451-specific T cells. (B) TcCA-2607-61-
specific T cells. Cells from 6 patients in asymptomatic phase (IND) and 11 patients with the cardiac form (CCC) were analyzed. Median values are
represented by horizontal lines. Error bars represent standard deviation intervals. Statistical analyses were carried out using Mann-Whitney U test (#) and
Kruskal—Wallis test with Dunn correction (*). Statistically significant differences are indicated (#) or (*) p0.05, (# #) or (**) p0.01, (# # #) or (***) p 0.001.
doi:10.1371/journal.pone.0122115.g004
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lymphocytes [53]. Secretion of anti-inflammatory cytokines (IL-4 and IL-10) was not detected
in any of the samples isolated from the patients evaluated in the present study after TcCA-2—
epitopes stimulation.
The experiment carried out with labeled dextramer loaded with the TcCA-2442-451 and
TcCA-2607-615 peptides showed that Chagas patients in both IND and CCC phase presented a
similar percentage of epitope-specific CD8+ T cells. A combined use of these dextramers with
different surface markers shows the existence of a differential phenotypical profile in cells from
IND versus CCC Chagas patients. Thus, IND Chagas patients present a significantly higher
amount of TcCA-2442-451 and TcCA-2607-615 epitope-specific CD8
+ T cells with a TNAIVE phe-
notype than cardiac phase patients. However, in cardiac chronic patients there is a predomi-
nant effector memory (TEM) phenotype or a terminally differentiated effector CD8
+ T cells
(TEMRA) phenotype. The effector phenotype observed in epitope-specific CD8
+ T cells isolated
from CCC patients does not correspond to an effector response, characterized by cytokine pro-
duction. In fact, our results show that the TcCA-2 epitope-specific CD8+ T cells isolated from
patients undergoing asymptomatic phases secreted higher IFN-γ and TNF-α than the TcCA-2
epitope-specific CD8+ T cells isolated from symptomatic patients. A higher clinical severity has
been described in patients with a low count of T. cruzi antigen specific IFN-γ producing CD8+
T cells [54,55]. Likewise, similar results have been obtained in experimental T. cruzi chronic in-
fection mouse models, in which most of the CD8+ T cells infiltrated in the cardiac tissue ex-
press surface markers of an effector memory phenotype although its effector activity in
response to antigenic activation remains poor [56]. This fact can be a consequence of a func-
tional alteration of these lymphocytes associated with the symptomatic status of the disease.
The alteration in the antigen-specific CD8+ T cells response may lead to a progression of the
disease related to the persistence in the host and the parasite load. It is known that a persistent
infection leads to a progressive functional alteration of the CD8+ T cells immune response
characterized by a lack of proliferation capacity, low expression of IL-7 receptor (CD127), as
well as a reduced TNF-α and IFN-γ production [57,58].
Our results show that in IND and CCC patients the percentage of fully differentiated epi-
tope-specific CD8+ T cells having a CD127-/CD45RA+ phenotype is higher than that having
an early differentiation CD127+/CD45RA- phenotype. Furthermore, the percentage of epitope-
specific CD8+ T cells with CD127+ phenotype is lower in CCC patients than in IND patients.
CD127 is a marker that identifies memory CD8+ T cells precursors capable of generating long
lived antigen-independent memory CD8+ T cells [30]. Moreover, it has been shown that pro-
longed antigen exposure during chronic parasitic, viral and bacterial infections results in failure
of memory CD8+ T cells able to acquire the properties of antigen independent memory T cells
[31,57]. The analysis of the CD57+ and CD44+ surface markers associated with clonal senes-
cence [59] and antigen experience [60], respectively, shows the existence of a significantly
higher percentage of senescent CD8+ T cells in CCC patient than in IND patients specific for
both TcCA-2442-451 and TcCA-2607-615 epitopes. In summary, our data suggest that there is a
gradual clonal exhaustion associated with increased disease severity, which might be the result
of continuous antigenic stimulation by persistent parasites. In the chronic phase of Chagas
heart disease it has been suggested that parasite persistence and immunological mechanisms
are inextricably related to the myocardial aggression [9,61]. However, it has also been described
that there is heart tissue damage in the absence of detectable live parasites [62]. We observed
that 57% of the Chagas disease patients included in the analysis were PCR positive (data not
shown). Currently, we are in the process of analyzing the dynamic of the phenotypic profile
and functionality of TcCA-2 epitope-specific CD8+ cells after treatments with benznidazole in
a large number of infected subjects at different stages of the disease.
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